Pain response and health-related quality of life analysis in patients with metastatic castration-resistant prostate cancer receiving cabazitaxel versus abiraterone or enzalutamide in the CARD study.

ASCO-GU 2020 Congress – Abstract No. 16. Fizazi K. et al

Conclusion:

“CBZ was associated with a greater pain response and delayed pain progression vs ARTA. CBZ and ARTA were associated with similar trends in HRQL but time to FACT-P deterioration was longer with CBZ vs ARTA.”

 

Quelle:

https://s3.amazonaws.com/files.oncologymeetings.org/prod/s3fs-public/2020-02/GU20-Proceedings-corrected-reduced.pdf?null